- Home
- / Anxo Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Anxo Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
NT$32
2024-10-29
Market Capitalization
NT$1.8 B
2024-10-29
Revenue
NT$895.3 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 849.9M | 877.9M | 866.1M | 824.1M | 866.3M | 939.9M | 895.3M |
| Cost of goods sold | 437.4M | 472.5M | 428.8M | 418.1M | 460.6M | 468.5M | 493.0M |
| Gross profit | 413.1M | 407.3M | 437.9M | 408.2M | 406.9M | 473.2M | 409.0M |
| Gross profit margin, % | 50.3% | 45.7% | |||||
| Operating expense total | 285.2M | 273.9M | 299.2M | 291.8M | 325.2M | 343.8M | 381.9M |
| Depreciation and amortization | 75.0M | 86.2M | 81.0M | 74.4M | 74.2M | 74.6M | 76.9M |
| EBITDA | 127.9M | 133.4M | 138.7M | 116.4M | 81.7M | 129.4M | 27.1M |
| EBITDA margin, % | 13.8% | 3.0% | |||||
| EBIT | 53.0M | 47.2M | 59.0M | 42.2M | 8.0M | 54.4M | (51.2M) |
| EBIT margin, % | 5.8% | -5.7% | |||||
| Interest income | 285.0K | 865.0K | 715.0K | 1.1M | 1.7M | 3.9M | 5.6M |
| Interest expense | 15.8M | 16.8M | 14.2M | 12.8M | 15.2M | 18.1M | 16.7M |
| Pre tax profit | 39.1M | 29.4M | 48.9M | 24.3M | (4.7M) | 38.7M | (60.0M) |
| Income tax expense | 9.6M | 7.6M | 10.3M | 4.6M | 2.3M | 7.9M | (5.9M) |
| Net Income | 29.6M | 21.8M | 38.6M | 19.7M | (7.0M) | 30.8M | (54.1M) |